Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
Abstract Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-05-01
|
| Series: | BMC Pulmonary Medicine |
| Online Access: | https://doi.org/10.1186/s12890-021-01513-7 |